Known true · enters 1 Oct 2027
Rules 1.1.0 · as of 14 Sep 2026
Christian Angermayer · Said 1 Oct 2025 · angermayer-0126
Quote
“I believe atai is the sector. Big Pharma is late. Very late. If they want exposure, they'll likely need to partner.... with us.”
Same tweet; he predicts large pharma will need to partner with atai to get psychedelic exposure, and adds 'No need to sell out.'
Intake
- EventA proposition written from a template on the asset, with a resolution criterion and a named public source, before the outcome is looked up. The same event resolves every person's items on it. Method ›
- A large pharmaceutical company partners with atai on a psychedelic program
- AreaOne of five topic classes: regulatory decisions, clinical trial outcomes, company and market outcomes, payer and policy, practice adoption. Every event has one area. Method ›
- Company and market outcomes
- DeadlineThe date by which the event must happen for the item to be true. It comes only from the person's words through the anchor table. Method ›
- None stated · undated panelItems with no deadline in the person's words, scored on a uniform 24-month window from the statement date. Part of the headline panel since rules 1.1.0; also shown on its own. Method ›, 24-month window to 1 Oct 2027
- Probability
- 0.70 LexiconThe fixed five-bin table that turns a phrase into a probability. The strongest phrase in the claim sentence decides; coders never read tone. Method › · binOne of five lexicon steps: A 'will' 0.90, B 'probably' 0.70, C 'may' 0.50, D 'unlikely' 0.30, E 'never' 0.10. A stated number goes to the nearest bin for calibration only. Method › B · “they'll likely need to partner.... with us”
- Base rateThe probability a published external study gives an event of that class and stage, fixed at intake. Halved when the item window is shorter than the class median time to decision. Never learned from the ledger's own items. Method ›
- None in the table
- Tags
- affiliated, retrospective
- Coder BCohen's kappa: agreement between two coders beyond chance, from -1 to 1. Reported for admit, event, deadline, bin and asserts from the second-coder match test. Method ›
- admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · event E-0110 · deadline none · bin B
Registry entry
atai Life Sciences announces a partnership, collaboration or licensing agreement with a large pharmaceutical company for one of its psychedelic programs.
TRUE on the date of the definitive public announcement (atai press release or SEC filing) of a partnership, collaboration, co-development or licensing agreement between atai Life Sciences, under any corporate name including AtaiBeckley or a successor, and a large pharmaceutical company, for one of atai's psychedelic programs. A large pharmaceutical company is one with annual revenue at or above US$10 billion in its last reported fiscal year. Rumours, letters of intent and non-binding term sheets do not count. An equity investment, a financing, a supply contract or a service contract without a program agreement does not count. FALSE at the deadline when no such announcement exists.
Resolution source: atai Life Sciences press releases; SEC EDGAR filings
Readings: 'If they want exposure, they'll likely need to partner... with us' is read as an announced agreement between atai and a large pharmaceutical company; the counterparty decides, so the words are a prediction about an event, not an intention.; 'Big Pharma' is read as a pharmaceutical company with annual revenue at or above US$10 billion.
How to read
Coder A
Resolution
- State
- Known trueAn item whose event has already happened but whose deadline has not passed. Shown as 'known true, enters on <deadline>'; pending in every metric until then. Method ›
- Effective deadlineAn item enters the score only when its deadline has passed and the outcome is true or false. A claim already known true still waits for its deadline. Method ›
- 1 Oct 2027
- Outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method ›
- occurred on 16 Jul 2026 · checked through 14 Sep 2026
- Resolver note
- AtaiBeckley signed an Agreement and Plan of Merger with Eli Lilly and Company on 2026-07-15 and announced it on 2026-07-16: $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in CVRs tied to BPL-003 and VLS-01 milestones. Lilly revenue is far above US$10B, so it is a large pharmaceutical company, and the agreement is definitive and covers atai's psychedelic programs. Caveat on the criterion: the deal is an acquisition, not a partnership, collaboration, co-development or licensing agreement. A strict reading of the enumerated deal types would give not_occurred. I follow the registry reading, which reads the words as 'an announced agreement between atai and a large pharmaceutical company'; an acquisition of the whole company and its psychedelic programs satisfies that reading. Flagged for adjudication.
- Evidence
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions (Form 8-K, Exhibit 99.1) · 16 Jul 2026
- AtaiBeckley Inc. Form 10-Q for the quarter ended June 30, 2026 (subsequent events: Agreement and Plan of Merger with Eli Lilly and Company dated July 15, 2026) · 11 Aug 2026
- Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley · 16 Jul 2026
Adversarial recheck
escalated (criterion): The criterion names four deal types: partnership, collaboration, co-development, licensing. The Lilly transaction is none of them. It is an Agreement and Plan of Merger signed 2026-07-15 and announced 2026-07-16, under which Lilly buys all shares for 6.75 US dollars plus a 2.50 CVR; the company is bought, not partnered with. The criterion also strikes out an equity investment or financing with no program agreement, which shows the drafter meant a narrow set of program deals. On that reading the state is not_occurred, because no other qualifying deal exists: the only big-pharma program agreement on record, Otsuka and Perception for arketamine, dates from 2021 and was terminated effective 2025-04-24. The event's own readings pull the other way, reading the words as 'an announced agreement between atai and a large pharmaceutical company', which an acquisition satisfies. Criterion and readings conflict; an adjudicator must pick.
How to read
Registry
Timeline
1 claim against 21 events in the field.
Company and market outcomes